Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P51812 (
mitogen-activated protein
)
10,636
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Specific docking interactions between
mitogen-activated protein
kinases (MAPKs), their regulators, and their downstream substrates, are crucial for efficient and accurate signal transmission. To identify novel substrates of the c-Jun N-terminal kinase (JNK) family of MAPKs, we searched the human genome for proteins that contained (1), a predicted JNK-docking site (D-site); and (2), a cluster of putative JNK target phosphosites located close to the D-site. Here we describe a novel JNK substrate that emerged from this analysis, the functionally uncharacterized protein
smoothelin-like 2
(
SMTNL2
).
SMTNL2 protein
bound with high-affinity to multiple MAPKs including JNK1-3 and ERK2; furthermore, the identity of conserved amino acids in the predicted docking site (residues 180-193) was necessary for this high-affinity binding. In addition, purified full-length
SMTNL2 protein
was phosphorylated by JNK1-3 in vitro, and this required the integrity of the D-site. Using mass spectrometry and mutagenesis, we identified four D-site-dependent phosphoacceptor sites in close proximity to the docking site, at S217, S241, T236 and T239. A short peptide comprised of the
SMTNL2
D-site inhibited JNK-mediated phosphorylation of the ATF2 transcription factor, showing that
SMTNL2
can compete with other substrates for JNK binding. Moreover, when transfected into HEK293 cells,
SMTNL2
was phosphorylated by endogenous JNK in a D-site dependent manner, on the same residues identified in vitro.
SMTNL2 protein
was expressed in many mammalian tissues, with a notably high expression in skeletal muscle. Consistent with the hypothesis that
SMTNL2
has a function in skeletal muscle,
SMTNL2 protein
expression was strongly induced during the transition from myoblasts to myotubes in differentiating C2C12 cells.
...
PMID:Combining docking site and phosphosite predictions to find new substrates: identification of smoothelin-like-2 (SMTNL2) as a c-Jun N-terminal kinase (JNK) substrate. 2398 1